盐酸丙酰左卡尼汀(Levocarnitine propionate hydrochloride) - 药物靶点：PDHK_在研适应症：外周血管疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

L-Carnitine propionate、Levocarnitine propionate hydrochloride (USAN)、Levocarnitine proprionate

+ [10]

靶点

PDHK

作用方式

刺激剂

作用机制

PDHK刺激剂(丙酮酸脱氢激酶刺激剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构-

非在研机构

Sigma-Tau Industrie Farmaceutiche Riunite SpA

李氏大药厂控股有限公司

兆科药业（合肥）有限公司广州分公司

+ [1]

最高研发阶段批准上市

首次获批日期

意大利 (1998-01-01),

心脏衰竭外周血管疾病

最高研发阶段(中国)终止

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H20ClNO4

InChIKeyKTFMPDDJYRFWQE-DDWIOCJRSA-N

CAS号119793-66-7

关联

60

项与盐酸丙酰左卡尼汀相关的临床试验

IRCT20170609034406N10

/ Suspended临床2/3期IIT

The potential effect of parenteral L-carnitine on hospitalized patients with moderate to severe COVID-19

开始日期2023-02-20

申办/合作机构

Tabriz University of Medical Sciences

IRCT20221128056646N1

/ Recruiting临床4期IIT

Assessment of effect of L-Carnitine supplement on subclinical LV systolic dysfunction detected by speckletracking echocardiography in patients with ESRD under hemodiylisis

开始日期2022-12-21

申办/合作机构

Shiraz University of Medical Sciences

IRCT20210412050944N2

/ Recruiting临床2期IIT

Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver in patients aged 5 to 15 years old

开始日期2022-09-23

申办/合作机构

Qazvin University of Medical Sciences

100 项与盐酸丙酰左卡尼汀相关的临床结果

登录后查看更多信息

100 项与盐酸丙酰左卡尼汀相关的转化医学

登录后查看更多信息

100 项与盐酸丙酰左卡尼汀相关的专利（医药）

登录后查看更多信息

497

项与盐酸丙酰左卡尼汀相关的文献（医药）

2025-04-01·Diabetes, Obesity and Metabolism

Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity

Article

作者: Antoniotti, Valentina ; Rabbone, Ivana ; Medina, Federico ; Prodam, Flavia ; Sista, Maria T. ; Monzani, Alice ; Bellone, Simonetta ; Agostini, Alida ; Baima, Jessica ; Partenope, Cristina ; Scotti, Lorenza ; Mancioppi, Valentina ; Solito, Arianna ; Dimarakis, Sotirios

AbstractAimTo assess the efficacy of the combined administration of myo‐inositol and zinc, a mineral involved in the insulin pathway, in paediatric obesity with insulin resistance on HOMA‐IR, glucose‐insulin metabolism, and lipid profile.Materials and MethodsDouble‐blind, randomized, placebo‐controlled study conducted in North Italy. Fifty‐six patients (10–18 years, Tanner stage ≥3) with obesity and insulin resistance were randomized to myo‐inositol (2000 mg), zinc gluconate (5 mg), and galactooligosaccharides (GOS) from plant‐based origin (1000 mg) (TRT) or placebo (PLC) containing only GOS from plant‐based origin (1000 mg). All patients received an isocaloric diet following the Mediterranean diet style. Data were collected at baseline (V0) and after 3 months (V1). The primary outcome was the insulin resistance index (HOMA‐IR).ResultsFifty out of 56 recruited subjects completed the study. TRT improved HDL cholesterol level compared to PLC (p = 0.05) but not insulin resistance. A stratified post hoc analysis was performed by sex, BMI, and subgroups of adherence to the Mediterranean diet. Subjects were divided for obesity grade, fasting insulin (p = 0.0137) and HOMA‐IR (p = 0.0273) were lower in TRT than in PLC patients, with a greater effect on severe obesity. No adverse events were detected.ConclusionThree months of supplementation with myo‐inositol and zinc were beneficial on lipid profile and in managing obesity complications at least in subjects with severe phenotype. Thus, myo‐inositol and zinc could be used as non‐pharmacological agents. This work suggests a long‐term study with a larger sample size to enrich the findings.

2025-01-01·Journal of Veterinary Dentistry

Serum Cortisol and Blood Glucose Concentrations in Anesthetized Dogs Administered Levobupivacaine and Low-Dose Dexmedetomidine for Regional Anesthesia of the Oral Cavity

Article

作者: Seliškar, Alenka ; Pavlica, Matic ; Nemec, Marija ; Kržan, Mojca ; Baš, Anže ; Nemec, Ana ; Kosjek, Tina

The effects on the stress response, postanesthetic sedation, and altered behavior were evaluated following regional anesthesia and dental treatment in 40 dogs. Serum cortisol and blood glucose concentrations were measured following the administration of levobupivacaine (LBUP) 0.5% and dexmedetomidine (DEX) (0.5 µg/kg) or a placebo. The dogs were randomly assigned to 4 groups of 10 dogs each. All dogs received a regional nerve block using LBUP 0.5%. Group 1 (LBUP + DEX IV) also received DEX intravenously (IV); group 2 (LBUP + PLC IV) also received a placebo IV; group 3 (LBUP + DEX IO) also received DEX in one infraorbital (IO) block; and group 4 (LBUP + DEX IA) also received DEX in one inferior alveolar (IA) block. Serum cortisol and blood glucose concentrations were determined before the administration of oral blocks and at the end of the procedure. Sedation and behavior scores were assessed before premedication and hourly for 6 h after the end of anesthesia. Cortisol concentration did not change in any group at either evaluation time. The glucose concentration was higher ( P < .05) only in the LBUP + DEX IA group at the end of the procedure. The sedation score was higher until the end of the observation period only in the LBUP + DEX IV and LBUP + PLC IV groups. No change in behavior score was observed in any of the groups. The reduction of perioperative stress response in all groups was due to the use of LBUP and not DEX.

2024-12-01·Psychiatry Research

Sex differences in response to intranasal oxytocin as an adjunctive therapy for patients with severe mental illness

Article

作者: Grossman-Giron, Ariella ; Sedoff, Omer ; Maoz, Hagai ; Tzur Bitan, Dana ; Bitan, Dana Tzur ; Baruch, Noam ; Mama, Yaniv ; Nitzan, Uri

Studies investigating the potential benefits of intranasal oxytocin (INOT) as an add-on treatment for patients with severe mental illness (SMI) have yielded inconsistent results, potentially due to sex differences in response to INOT. This study explored the differential effects of INOT among male and female patients with SMI. A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI. Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks. Sex moderated the effect of OT/PLC on the Hamilton Rating Scale for Depression (HRDS) (p < 0.001). A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity. This effect was not found for males. We conclude that the addition of INOT to the treatment of patients with SMI in an inpatient setting was beneficial for female patients, particularly reducing depressive symptoms, but not for male patients. Future studies should aim to identify patients who are more likely to benefit from INOT administration.

100 项与盐酸丙酰左卡尼汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04713	-	A16AA01	DB15980

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
外周血管疾病	意大利	-	1998-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溃疡性结肠炎	临床3期	欧盟	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
肾脏疾病	临床3期	欧盟	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
外周动脉闭塞性疾病	临床3期	美国	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
外周动脉疾病	药物发现	中国	李氏大药厂控股有限公司	2008-05-01
间歇性跛行	药物发现	美国	Alfasigma SpA	2006-04-01
外周血管疾病	药物发现	美国	Alfasigma SpA	2006-04-01
外周动脉闭塞性疾病	药物发现	美国	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2022	N/A	头颈部肿瘤	150	L-carnitine 500mg	(壓積淵艱衊壓鹹築網網) = 廠齋膚願觸餘壓淵獵齋窪築構獵觸蓋鏇壓顧築 (製積簾簾廠顧觸艱衊鑰 )	-	2022-09-10
				L-carnitine (Control)	(壓積淵艱衊壓鹹築網網) = 顧艱鑰醖範艱築顧鹹遞窪築構獵觸蓋鏇壓顧築 (製積簾簾廠顧觸艱衊鑰 )
NCT01107730 (CTgov)	临床3期	心房颤动	33	L-carnitine (L-Carnitine)	構膚繭繭鏇膚願築顧構(廠膚簾願壓蓋鹽夢蓋齋) = 觸膚壓獵積膚範夢構簾夢鏇構醖鬱廠醖鏇淵醖 (餘鬱廠選鏇獵廠遞鏇餘, 願範鏇蓋糧窪顧築繭夢 ~ 觸蓋鏇鏇願鏇鏇襯艱襯) 更多	-	2015-05-13
				Vitamin C (Vitamin C)	構膚繭繭鏇膚願築顧構(廠膚簾願壓蓋鹽夢蓋齋) = 壓觸鹹構築蓋願鏇艱網夢鏇構醖鬱廠醖鏇淵醖 (餘鬱廠選鏇獵廠遞鏇餘, 壓衊醖壓鏇遞鏇淵鑰憲 ~ 範壓遞獵鏇襯齋鹽顧壓) 更多
NCT00399919 (Pubmed \| J Cardiopulm Rehabil Prev)	临床3期	外周动脉疾病	69	Propionyl-L-carnitine	衊願築遞簾齋觸餘醖醖(壓觸獵鹹顧壓淵蓋餘齋) = 製蓋襯觸築製醖窪壓壓範鬱淵鏇窪蓋獵糧壓簾 (壓鹹選鬱鑰簾膚齋餘願 )	-	2011-03-01
				Placebo	衊願築遞簾齋觸餘醖醖(壓觸獵鹹顧壓淵蓋餘齋) = 觸築夢膚鏇獵鑰顧構網範鬱淵鏇窪蓋獵糧壓簾 (壓鹹選鬱鑰簾膚齋餘願 )